683 Capital Management

Active

Updated: Apr 2, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jul 20, 2021	Amylyx Pharmaceuticals	$135.0M Series C	Viking Global Investors	Belinda Termeer, Bain Capital Life Sciences, Falcon Edge Capital, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Woodline Partners
Jun 23, 2021	Tvardi Therapeutics	$74.0M Series B	683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie McNab	Sporos Bioventures

Total Raised

N/A

Valuation

N/A